Preliminary evaluation of alpha-emitting radioembolization in animal models of hepatocellular carcinoma

Yong Du\textsuperscript{1}, Angel Cortez\textsuperscript{2}, Anders Josefsson\textsuperscript{2}, Mohammadreza Zarisfi\textsuperscript{2}, Rebecca Krimins\textsuperscript{1}, Eleni Liapi\textsuperscript{1}, Jessie R. Nedrow\textsuperscript{2,*}

\textsuperscript{1} Russell H. Morgan Department of Radiology & Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America, \textsuperscript{2} Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States of America

* nedrowj@upmc.edu

Abstract

Hepatocellular carcinoma is the most common primary liver cancer and the fifth most frequently diagnosed cancer worldwide. Most patients with advanced disease are offered non-surgical palliative treatment options. This work explores the first alpha-particle emitting radioembolization for the treatment and monitoring of hepatic tumors. Furthermore, this work demonstrates the first \textit{in vivo} simultaneous multiple-radionuclide SPECT-images of the complex decay chain of an \(^{225}\text{Ac}\)-labeled agent using a clinical SPECT system to monitor the temporal distribution. A DOTA chelator was modified with a lipophilic moiety and radiolabeled with the \(\alpha\)-particle emitter Actinium-225. The resulting agent, \(^{225}\text{Ac}\)-DOTA-TDA, was emulsified in ethiodized oil and evaluated \textit{in vivo} in mouse model and the VX2 rabbit technical model of liver cancer. SPECT imaging was performed to monitor distribution of the TAT agent and the free daughters. The \(^{225}\text{Ac}\)-DOTA-TDA emulsion was shown to retain within the HEP2G tumors and VX2 tumor, with minimal uptake within normal tissue. In the mouse model, significant improvements in overall survival were observed. SPECT-imaging was able to distinguish between the Actinium-225 agent (Francium-221) and the loss of the longer lived daughter, Bismuth-213. An \(\alpha\)-particle emitting TARE agent is capable of targeting liver tumors with minimal accumulation in normal tissue, providing a potential therapeutic agent for the treatment of hepatocellular carcinoma as well as a variety of hepatic tumors. In addition, SPECT-imaging presented here supports the further development of imaging methodology and protocols that can be incorporated into the clinic to monitor Actinium-225-labeled agents.

Introduction

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the fifth most frequently diagnosed cancer worldwide, as well as the second most frequent cause of cancer death \cite{1–5}. Most patients with advanced disease are offered only non-surgical palliative
treatment options, including systemic chemotherapy, radiofrequency ablation, or intra-arterial therapies [5]. Hepatic tumors derive their blood supply primarily from the hepatic artery, whereas normal liver is mainly fed by the portal vein. Image-guided intra-arterial therapies, such as transarterial embolization (TAE), chemoembolization (TACE) and radioembolization (TARE), exploit the arterial route to selectively deliver therapy to tumors. However, these therapies have several limitations, urging the development of new treatment strategies [6, 7].

Ethiodized oil is an FDA-approved radio-opaque agent composed of a variety of oils including the ethyl esters of fatty acids of poppy seed oil. Ethiodized oil can be targeted to hepatic tumors through selective injections via the hepatic artery, where it is able to embolize hepatic tumors, accumulating and remaining in the tumors while clearing out of normal liver tissue [8, 9]. The selective targeting and embolization of hepatic tumors makes ethiodized oil an excellent vehicle for the selective delivery of therapeutic radionuclides. β-particle emitting radiopharmaceutical therapies, such as the commercially available Yttrium-90 glass or resin microspheres have been developed over the past 20 years [6, 10] but have shown limited survival benefits in patients with HCC as compared to TACE, the standard of care treatment option. Compared to Yttrium-90 microspheres that accumulate into arterioles, β-emitting agents, such as [131I]I-ethiodized oil, seem to be directly uptaken by tumor cells, resulting in a higher tumor radiation dose [11]. However, HCC patients treated with [131I]I-ethiodized oil vs. TACE had similar survival up to three years post-treatment; yet patients that had a portal vein thrombosis or more advanced disease demonstrated a significantly higher mean survival as compared to patients treated with TACE [11]. The incorporation of Iodine-131 into ethiodized oil is costly and the exploration of alternate β-particle emitting radionuclides has been explored, such as a Rhenium-188 chelate emulsified into ethiodized oil [12–14]. Despite initial efficacy of the [188Re]Re emulsion, the increased hepatic and hematologic toxicities have been a concern [14]. In addition, the low energy transfer of β-particles introduces the ability of the remaining tumors to develop resistance mechanisms further limiting the treatment options for patients [15, 16].

Targeted alpha therapy (TAT) has emerged as a highly potent treatment for cancer [17–19]. The high potency of TAT impacts normal tissue as well, highlighting a need to accurately determine absorbed doses to provide well-defined dosing strategies and effective treatment while minimizing toxicities. Currently, surrogate imaging agents are utilized to evaluate TAT agents; however, complex decay schemes of α-particle emitting radionuclides are not accurately portrayed using surrogate imaging strategies, urging the development of methodologies and instrumentation to image α-particle emitting radionuclides. Actinium-225 is one of the α-particle emitting radionuclides currently being explored in the clinic. Actinium-225 has a complex decay scheme and energy spectrum (Fig 1). The decay of Actinium-225 and its daughters primarily releases energy as α-particles (Fig 1A); however, γ-emissions suitable for SPECT imaging occur (i.e. at 218 keV and 440.45 keV), but are in low abundance (Fig 1B). Please note, eventhough there are several low abundant X-rays from Actinium-225 and its decay daughters at the 70 keV to 90 keV energy range, the peak around 80 keV shown in Fig 1B is dominated by the lead X-rays generated from interactions of high-energy photons with the collimator. This is a well known phenomena in SPECT physics [20]. In addition, this region is also heavily contaminated by downscatter, and thus should not be used for imaging on current clinical SPECT systems. The activity administered for TAT is extremely small due to their high potency, compounding the low abundance of rays suitable for imaging and resulting in a small number of γ photons for SPECT imaging. Furthermore, the initial α-particle decay with its high recoil energy breaks the bonds within the chelate, resulting in the release of the free decay daughters. These decay daughters may migrate to other organs, complicating dosimetry calculations. Surrogate imaging radionuclides do not replicate the complex decay schemes that
are commonly found for $\alpha$-particle emitting radionuclides. Therefore, it is urgent and essential to develop quantitative SPECT imaging methodologies specifically for these TAT radionuclides to improve the accuracy and precision of the imaging and the resulting knowledge of the distributions and dose deposition of the agent and its daughters.

In this study we investigate the potential of an $^{225}$Ac-labeled chelate emulsified in ethiodized oil as a TARE agent to selectively target liver tumors. Furthermore, we evaluated the prospect of using a clinical SPECT/CT system to image and monitor the distribution of the $^{225}$Ac-labeled TARE agent as well as its daughters in the VX2-tumor bearing rabbit model over a 6-day window.

**Materials and methods**

**Reagents**

All chemicals were purchased from Sigma-Aldrich Chemical Co. (ST. Louis, MO, USA) or Thermo Fisher Scientific (Pittsburgh, PA, USA), unless otherwise specified. DOTA-tris(t-Bu ester) was purchased from Macrocyclics, Inc. (Dallas, TX, USA). Indium-111 (InCl$_3$) was purchased from BWZXT ITG Canada, Inc. (Ottawa, ON, Canada). Actinium-225 nitrate was purchased from Oak Ridge National Laboratory (Oak Ridge, TN, USA).

**Chemical syntheses.** DOTA-tris(t-Bu ester)-TDA was synthesized as previously described with modifications [21]. Briefly, the DOTA-tris(t-Bu) ester (50 mg, 0.09 mmol) and HBTU (0.168 mg, 0.44 mmol) were dissolved in 2 mL of DMF. The resulting solution was stirred for 30 minutes at room temperature (RT) then 1-tetradecylamine (TDA) (22 mg, 0.11 mmol) and DIPEA (76 $\mu$L, 0.44 mmol) were added to the solution, which was stirred overnight at RT. The solution was extracted with ethyl acetate washed with water (2x) then brine (1x). The ethyl acetate solution was dried over MgSO$_4$, filtered and the ethyl acetate was evaporated under vacuum to yield a yellow powder. The DOTA-tris(t-Bu ester)-TDA was purified by silica gel chromatography (eluent: hexane/ethyl acetate, 3/1 v/v), purity confirmed by TLC and the product was used without further confirmation.
DOTA-TDA. DOTA-tris(t-Bu ester)-TDA (30 mg, 0.04 mmol) was dissolved in trifluoroacetic acid (125 μl) and dichloromethane (400 μl) and stirred overnight at RT. The solvent was evaporated under vacuum yield a pure white solid, 51.3% was recovered. DOTA-TDA was successfully synthesized (overall yield 53.1%) and confirmed by mass spectrometry. DOTA-TDA was confirmed by using a Thermo Scientific Q Exactive Plus Orbitrap Mass Spectrometer coupled with a Vanquish UPLC system at the Metabolomics Facility at Johns Hopkins School of Medicine (Director–Dr. Anne Le) (M+H): calculated 600.4336, found 600.4316; (M-H) calculated 598.4185 found 598.4203.

Radiolabeling of DOTA-TDA. For radiolabeling the following were added to acid wash Eppendorf tube 1 μl of Indium-111, 40 μl of 0.4M NaOAc buffer pH = 4.5, and 1 μl of DOTA-TDA (1 μg/μl). The solution was heated at 95˚C for 15 minutes and purified using a Waters Sep-Pak C18 (Milford, MA, USA). [111In]In-DOTA-TDA was eluted with ethanol, dried, and resuspended in sterile PBS with greater that 95% radiopurity as determined by thin layer chromatography (TLC).

For Actinium-225, 5 μl of Actinium-225 solution, 5 μl of 2M Tris buffer pH = 7, and 2.5 μL of DOTA-TDA were added to an acid washed tube, heated at 95˚C for 15 minutes. Radiolabeling yields were ≥95%; [225Ac]Ac-DOTA-TDA was used without further purification.

Partition coefficient (Log P). Log P were determined for the radiolabeled conjugates, [111In]In- or [225Ac]Ac-DOTA-TDA, were dissolved in 1 mL of octanol in a centrifuge tube. The centrifuge tube was vigorously vortexed for a minute with 1 mL of 0.9% saline. The tube was centrifuged at 1000 rpm for 5 minutes and allowed to sit for 30 minutes until the phases were clearly separated. The organic phase (Octanol) and the aqueous phase (Saline) were collected separately and counted at equilibrium of Actinium-225 in an automatic γ-well counter (Perkin-Elmer 2470 WIZARD2 Automatic Gamma Counter, Waltham, MA, USA). The Log P values were calculated using the following formula: Log P = Log ([Counts]octanol/[Counts]saline).

Animal studies
This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Animal Care and Use Committee of the Johns Hopkins University School of Medicine (Protocol Number: M019M321; RB19M81). All the animals in this study were monitored daily for health and behavior. Rabbit surgery was performed under a mixture of ketamine and xylazine, and the anesthesia was maintained with isoflurane in oxygen. The rabbits were euthanized at pre-determined timepoints using Ethansol®. The mice were euthanized at pre-determined timepoints by isoflurane overdose and cervical dislocation. Mice in the survival study were observed for signs of pain and distress (lethargy, hunched back, paralysis, etc.), weight loss, and tumor size [volume = 0.5 x (length x width²)]. The mice in the survival study were euthanized as described above if one of the following conditions were met: 1. weight loss (>20%); 2. primary tumor reaching 1,500 mm³; 3. signs of pain or distress; or 4. 180 days post-treatment. In this study a total of 33 NCG male mice and 3 adult New Zealand rabbits were used. All efforts possible were made to minimize suffering of the animals in this study. All sacrificed animals met the described end-point criteria, no animals died prior to end-points.

Animal studies were performed using 7-8-week-old healthy male NCG mice obtained from Charles River Laboratories (Wilmington, MA, USA). Adult New Zealand rabbits were used weighing approximately 4 kg (Myrtle’s Rabbitry, Thompson Station, TN, USA). For tumor retention and survival studies the mice were injected subcutaneously in the right flank with approximately 1 x 10⁶ HEP2G cells in 100 μL of sterile PBS and Matrigel (1:1).
**Mouse model.** Tumor retention. Biodistribution studies were carried out as previously described in healthy NCG male mice (n = 3/group) bearing HEP2G subcutaneous tumors [22, 23]. To assess tumor retention the mice were divided into two groups that were injected intratumorally with $^{111}$In-DOTA-TDA (37 kBq, 60 μL) alone or $^{111}$In-DOTA-TDA (37 kBq, 60 μL) emulsified in ethiodized oil. At 48-hours post-injection (p.i.), the mice were euthanized. The blood, heart, lungs, liver, spleen, kidneys, stomach (with content), intestines (with content), bone, muscle, and tumors were harvested, weighed, and measured in an automatic \( \gamma \)-well counter. The percentage of injected dose per gram (%ID/g) was calculated by comparison with a weighed, diluted standard.

**Therapeutic efficacy: Survival studies.** Subcutaneous liver cancer models were used to evaluate the preliminary therapeutic efficacy of $^{225}$Ac-DOTA-TDA/ethiodized oil emulsions. The following treatments were administered in subcutaneously HEP2G tumors (266.5 ± 23.2 mm\(^3\)): 1. Saline (60 μL) 2. Ethiodized oil alone (60 μL) or 3. $^{225}$Ac-DOTA-TDA/ethiodized oil (37 kBq, 60 μL). Survival fractions were plotted as a Kaplan-Meier survival curve using Prism 8 (GraphPad; La Jolla, CA, USA).

**VX2 rabbit model.** Anesthesia. Rabbits were administered a mixture of ketamine (30–50 mg/kg) and xylazine (3–5 mg/kg) intramuscularly prior to tumor harvesting, implantation, and imaging. Anesthesia was maintained with 3% isoflurane in oxygen as well as additional injections of the ketamine/xylazine solution.

Ultrasound guided tumor implantation. The implantation of the VX2 tumor was done as previously described with modifications [24]. Briefly, the solid VX2 tumor for implantation was obtained from a carrier rabbit that had been injected intramuscularly in the thigh approximately 2 weeks prior. The VX2 tumor was harvested, placed in 0.9% sodium chloride, and minced into small pieces. The minced tumor was prepared in a 16-gauge Angiocath (2 inches long), using ultrasound guidance, the needle punctured the liver and the tumor pieces were pushed into the liver with a guide wire. Manual compression was administered after the needle was removed.

Intrahepatic arterial injection including agents and dosing. Hepatic angiography was performed as previously described [24]. Briefly, rabbits with VX2 hepatic tumors, confirmed by ultrasound were anesthetized and surgical cutdowns were performed to expose the femoral artery. A 4-F sheath (Cook) was inserted to allow a 2-F catheter tip (JB1 catheter; Cook) to access the common hepatic artery. Fluoroscopy was utilized to select the arterial branch and radioembolization was performed.

SPECT imaging in VX2-bearing rabbit. SPECT/CT imaging was performed on a Siemens Symbia T16 SPECT/CT system. The anesthetized rabbit (n = 1) was placed supine on the imaging bed with the whole body in the field-of-view. The images were acquired at 24 hours, 72 hours and 6 days p.i. Projection data were acquired in 120 views over 360˚ with a 128 x 128 matrix and 4.795 mm pixel size. The imaging time were 75 seconds per view for the 24-hour imaging, and 90 seconds per view for the 72-hour and 6-day imaging. The high-energy collimators were used. Data were binned into two energy windows—20% centered at 440.45 keV peak of Bismuth-213 and 20% centered at 218.2 keV peak of Francium-221, respectively. Both isotopes are daughters of Actinium-225 decay and emit gamma photons that can be imaged by SPECT. Francium-221 has a short half-life of 4.9 minutes, therefore its distribution represents those of Actinium-225’s. Bismuth-213 has a half-life of 45.6 minutes and could have redistributed from the parent isotope. After SPECT acquisition, a CT scan was performed to provide anatomical images and an attenuation map. The SPECT images were reconstructed with Siemens Flash3D OSEM algorithm with compensation for attenuation and resolution [25]. A total of 6 iterations with 15 subsets per iteration were used.

SPECT imaging analysis. Volumes of interest (VOIs) were drawn on the SPECT/CT images for the normal organs/tissues liver, kidneys, muscle (left thigh muscle) and the tumor using
the software VivoQuant™ version 4.0 patch 3 (Invicro Imaging Services and Software, Boston, MA, USA) using a method developed by Plyku et al. [26]. The method was developed for tumor counting for SPECT imaging to take into consideration the spill-out or partial volume effect, the method has also been used for small normal tissues/organs as the pituitary gland [27].

Ex vivo biodistribution VX2-bearing and non-tumor bearing rabbits. Biodistribution studies were carried out following the SPECT imaging approximately 6-days post-injection of $^{225}$Ac Ac-DOTA-TDA (0.49 MBq) emulsified in 1 mL of ethiodized oil in the VX2-bearing rabbit ($n = 1$) and at approximately 24 hours for non-tumor bearing rabbits ($n = 2$). At the end time-point the rabbits were euthanized (Ethansol® 1 mL minimum then 1mL/4.5 kg). The blood, heart, lungs, liver, spleen, kidneys, stomach, intestines, marrow, femur+marrow, muscle, gall bladder, bile, and if applicable the tumor were harvested, weighted, and measure in an automatic γ-well counter and/or a Capintec CRC-7 dose calibrator at equilibrium of Actinium-225. The percentage of injected dose per gram (%ID/g) was calculated based on the dose injected and converted to Bq/g using an efficiency coefficient.

Statistical Analysis was performed using the software Graphpad Prism 8. All data are presented as mean ± SD. Tumor retentions were compared using 2-way ANOVA. Survival studies used Kaplan-Meier curves that were analyzed using the Log Rank (Mantel-Cox) test. Values were considered significant when $P<0.05$.

Results

Radiochemistry

$^{111}$In-DOTA-TDA was radiolabeled at a specific activity of 2.13 MBq/nmol with greater than 95% radiopurity following purification. The $^{225}$Ac-DOTA-TDA was radiolabeled at a specific activity of 0.36 MBq/nmol with greater than 95% radiolabeled yield.

Determining partition coefficients (LogP)

The LogP for $^{111}$In-DOTA-TDA was 1.57 ± 0.01 and the LogP for $^{225}$Ac-DOTA-TDA was 1.65 ± 0.02. For comparison, doxorubicin, a chemotherapeutic used for TACE, has a reported LogP of 1.27 [28].

Tumor retention of $^{111}$In-DOTA-TDA emulsion

The retention of $^{111}$In-DOTA-TDA alone or as an emulsion (Fig 2, S1 Table) were compared 48-hours p.i. using a 2-way ANOVA test in HEP2G tumor-bearing mice. The $^{111}$In-DOTA-TDA emulsion had significantly higher uptake within the tumor as compared to $^{111}$In-DOTA-TDA alone after 48 hours (216±145%ID/g vs. 20.0±15.9%ID/g; $p \leq 0.0001$), supporting the statement that ethiodized oil is able to retain the proposed agents in a model of liver cancer.

Therapeutic efficacy: Survival studies

Kaplan-Meier survival curves (Fig 3, S2 Table) showed significant improvement in survival of HEP2G tumor-bearing mice when treated with $^{225}$Ac-DOTA-TDA emulsions as compared to both the untreated control ($p<0.005$) and ethiodized oil alone ($p<0.001$). The median survival for $^{225}$Ac-DOTA-TDA emulsions in treated mice was 45 days, ranging from 26–87 days, as compared to 24-days (untreated, [15–29 days]) and 26-days (ethiodized alone, [15–40 days]). In addition, the rate of tumor growth in the $^{225}$Ac-DOTA-TDA emulsions
treated group was slowed as demonstrated by the individual tumor growth curves (Fig 4, S3–S5 Tables).

**SPECT imaging in VX2-bearing rabbit**

The fused SPECT/CT images from 24, 72, and 144-hours p.i. (Fig 5) demonstrated that the activity of $^{225}$Ac-DOTA-TDA emulsion agent accumulated mainly in the VX2 tumor with gradual clearance out of normal liver tissue. At 72 hours and 6-day p.i., the $^{225}$Ac-DOTA-
DOTA-TDA emulsion agent is concentrated within the tumor; however, the figures clearly show that there were differences in the distributions between the Francium-221 energy window and Bismuth-213 energy window—there was increased signal in the normal liver tissue above the tumor in the Bismuth-213 window, most likely associated with the escape of the free Bismuth-213 daughter from TARE agent.

**SPECT imaging analysis**

The tumor to liver ratio on the SPECT/CT images regarding the Francium-221 energy window for 24, 72 hours and 6-days were approximately 23:1, 20:1 and 27:1, respectively, and the corresponding tumor to muscle ratios were 265:1, 207:1 and 191:1, respectively. Regarding the Bismuth-213 energy window the tumor to liver ratio on the SPECT/CT images for 24, 72 hours and 6-days were 15:1, 16:1 and 21:1, respectively, and the corresponding tumor to muscle ratios were approximately 186:1, 141:1 and 118:1, respectively.
Ex-Vivo biodistribution in VX2-bearing rabbit

Following the SPECT imaging, biodistribution studies were carried out in the VX2-tumor bearing rabbit at 6-days p.i. of [225mAc]Ac-DOTA-TDA emulsion (Table 1). Accumulation of the TARE agent was predominately in the VX2 tumor (40.6%ID/g). The next highest uptake was seen in the normal liver tissue (0.23%ID/g), resulting in having approximately 177:1 tumor to liver ratio (Table 2). The TARE agent accumulation in normal tissues were minimal, only slightly above background as determined by uptake in the muscle (0.001% ID/g). This low uptake in normal tissue is consistent with the ex-vivo biodistributions in non-tumor bearing rabbits (n = 2) at approximately 24-hours p.i. via the hepatic artery as shown in Table 1.

Fig 5. SPECT/CT images of a rabbit with VX2 hepatic tumor. Fused SPECT/CT images of rabbit with a VX2 hepatic tumor at 24, 72 and 144-hours post-injection of [225mAc]Ac-DOTA-TDA emulsion. Left Panels: Francium-221 energy window. Right panels: Bismuth- 213 energy window. https://doi.org/10.1371/journal.pone.0261982.g005
Due to its indolent course, most patients with HCC have advanced and unresectable disease at the time of diagnosis and are being offered only non-surgical palliative treatment options [5, 6]. In addition, the liver is also the most common site for metastatic disease, including colorectal liver metastases. Intra-arterial therapies are widely used for treatment of patients with HCC or metastatic liver cancer [5]. Nevertheless, these therapies have shown limited survival benefit for patients with HCC, urging the need for developing novel improved therapeutic strategies [5, 29–33].

β-emitting radiopharmaceutical agents have shown promising results but the survival benefits in patients with HCC are comparable to the standard of care, TACE [34]. TAT provides highly potent agents [35–48] that are highly damaging to tumor cells, effectively causing irreparable DNA damage to tumor cells, needing only a few α-tracks as compared to $10^3$–$10^4$ tracks for a β-emitting agents. Consequently, there is growing interest in TAT agents for cancer therapy [49–51]. Recently, the first in human experience with $^{213}$Bi-DOTATOC, a TAT agent for neuroendocrine cancer, was selectively targeted via the hepatic artery to treat metastatic disease in the liver of neuroendocrine cancer patients not responding to standard therapies as well as $^{177}$Lu-Lu-DOTATOC, a β-emitting targeted therapy. Kratochwl et al. demonstrated in a small subset of patients that $^{213}$Bi-DOTATOC was able to overcome refractory disease and provided positive responses in patients [52]. Biomarkers for targeted radiopharmaceutical

### Table 1. Ex vivo biodistribution of $^{225}$Ac-DOTA-TDA in a technical rabbit model.

| Organs          | Tumor-bearing 6 days p.i. | Non-tumor bearing 23.5 hours p.i. | Non-Tumor bearing 28 hours p.i. |
|-----------------|---------------------------|----------------------------------|---------------------------------|
|                 | %ID/g Bq/g                | %ID/g Bq/g                        | %ID/g Bq/g                      |
| Blood           | 0.001 4.291               | 0.006 161.4                       | 0.036 592.2                     |
| Heart           | 0.002 5.641               | 0.003 94.95                       | 0.004 59.36                     |
| Lungs           | 0.014 46.23               | 0.028 781.0                       | 0.023 382.0                     |
| Liver           | 0.233 753.2               | 0.153 4352                        | 0.172 2796                      |
| Spleen          | 0.092 296.4               | 0.078 2214                        | 0.092 1495                      |
| Kidneys         | 0.020 64.59               | 0.039 1114                        | 0.045 731.0                     |
| Stomach         | 0.010 30.65               | 0.047 1346                        | 0.044 708.8                     |
| Intestines      | 0.020 826.3               | 0.031 880.3                       | 0.028 449.9                     |
| Marrow          | 0.018 66.02               | 0.013 372.1                       | 0.013 210.1                     |
| Whole Bone      | Indistinguishable from background | 0.054 1521 | 0.011 182.7 |
| Muscle          | 0.001 2.637               | 0.001 18.54                       | 0.002 26.93                     |
| Gall Bladder    | 0.081 260.134             | 0.098 1600.6                      | 0.105 2986.55                   |
| Bile            | 0.023 74.533              | 0.091 1483.13                     | 0.084 1812.35                   |
| Tumor           | 40.62 148370              | ---                              | ---                             |

*Organs were counted at equilibrium of Actinium-225 and its daughters.

https://doi.org/10.1371/journal.pone.0261982.t001

### Table 2. Tumor ratios based on SPECT imaging of francium-221 and bismuth-213.

| Time p.i | Francium-221 | Bismuth-213 |
|----------|--------------|-------------|
|          | Tumor:Liver  | Tumor:Muscle| Tumor:Liver | Tumor:Muscle |
| 24 h     | 23:1         | 265:1       | 15:1       | 186:1        |
| 72 h     | 20:1         | 207:1       | 16:1       | 141:1        |
| 6 d      | 27:1         | 191:1       | 21:1       | 118:1        |

https://doi.org/10.1371/journal.pone.0261982.t002
therapies are limited for HCC; however, the selective delivery of therapies via the hepatic artery for primary liver cancers are common. In this study, we investigated the potential to exploit intra-arterial delivery of the TARE agent, $^{225}$Ac-DOTA-TDA emulsion, for its ability to target primary liver tumors as well as its therapeutic efficacy in a mouse model of HCC.

Ethiodized oil has been demonstrated to have high selectivity and retention in the liver [53]; Ethiodized oil has shown to be retained in hepatic tumors for months [54]. $^{188}$Re-labeled chelators, modified to introduce lipophilicity, have been successfully incorporated into ethiodized oil for $\beta$-emitting radiopharmaceutical therapy [55]. Here, we used a similar approach and altered the DOTA chelator, which is suitable for $^{225}$Ac-labeling, by incorporating an alkyl side chain to introduce lipophilicity. The resulting agent, DOTA-TDA, was radiolabeled with both Indium-111 and Actinium-225 in high radiolabeling yields and purities. Both the $^{111}$In- and $^{225}$Ac-DOTA-TDA were shown to be lipophilic as determined by the partition coefficients, helping them to be emulsified. The emulsification of $^{111}$In-DOTA-TDA with ethiodized oil resulted in an approximate 11-fold increase in retention of the radiolabel agent within the mouse model of primary liver cancer. The preliminary potency of the TARE agent, $^{225}$Ac-DOTA-TDA emulsions was evaluated and demonstrated significant increases in survival in treated mice as compared to mice receiving saline or ethiodized oil alone. $^{225}$Ac-DOTA-TDA emulsions treated mice almost doubled (1.8x) their median survival as compared to the control groups, with the first treated mouse not reaching its endpoint until the median survival of the control. The preliminary results in the mouse model of primary liver cancer are promising, and we further evaluated the alpha-emitting TARE agent in a technical model to confirm selective delivery and retention via intra-arterial delivery.

The rabbit VX2 model provides a technical animal model for intra-arterial injections, allowing us to explore the selective delivery of $^{225}$Ac-DOTA-TDA emulsions to a hepatic tumor. We have confirmed delivery, accumulation, and retention of the TARE agent within the VX2 tumor by ex-vivo biodistribution, and in-vivo SPECT imaging of Actinium-225’s daughters (Francium-221 and Bismuth-213) using a clinical SPECT/CT system. Even though feasibility of SPECT imaging of Actinium-225 decay chain has been demonstrated [56, 57]—to our knowledge, this work is the first to demonstrate it can be done longitudinally in-vivo on a clinical SPECT/CT system with low activities. Furthermore, the fact that the two energy windows showed different tumor to liver/muscle ratios indicates the importance of using SPECT to monitor both parent and daughter isotopes. Clearance from normal tissues including the liver was seen in early biodistribution studies in non-tumor-bearing rabbits at approximately 24 hours p.i. of $^{225}$Ac-DOTA-TDA emulsions with the highest uptake, less than 0.2%ID/g, in the normal liver. The VX2-bearing rabbit’s biodistribution showed that the normal liver had slightly higher uptake (0.23%ID/g) of $^{225}$Ac-DOTA-TDA emulsion at 6-days p.i., most likely associated with clearance of the TARE agent from the VX2 tumor, which had 40.6%ID/g uptake at 6-days p.i. This is further confirmed by the SPECT images that demonstrated the stark contrast of the TARE agent within the tumor as compared to the normal liver tissue as well as the increase in the tumor to liver ratio at 6-days p.i. More importantly, the SPECT images also demonstrated the differences in the distribution of Actinium-225/Francium-221 from that of free Bismuth-213, indicating the importance of SPECT imaging for Actinium-225-labeled agents.

**Conclusion**

In summary, these studies demonstrate that the developed TARE agent, $^{225}$Ac-DOTA-TDA emulsions has promise as a therapeutic agent for hepatic tumors, including primary liver tumors. This work highlights that the combination of chelator labeled with a long-
lived $\alpha$-emitting radionuclide emulsified with ethiodized oil is capable of being selectively delivered to hepatic tumors, delivering a highly potent therapeutic dose to hepatic tumors over an extended period of time. Furthermore, we have shown that the $^{225}$Ac-labeled TARE agent can be imaged and longitudinally monitored through clinical SPECT imaging using its daughters Francium-221 and Bismuth-213 even with very low injected activity. The development of SPECT imaging methodologies to monitor the complex decay scheme of $\alpha$-emitting radionuclides, such as Actinium-225, and their daughters are important for accurately monitoring the distribution of TAT agents in-vivo over time through molecular imaging providing essential pharmacokinetic data to optimize the therapeutic efficacy. More importantly, these SPECT imaging methodologies can be implemented for $^{225}$Ac-labeled TAT agents currently in clinical trials helping to develop well-defined dosing strategies and optimal patient-specific treatment planning.

Supporting information
S1 Table. Raw %ID/g for biodistribution of $^{111}$In-DOTA-TDA emulsion and free. (PDF)
S2 Table. Raw data for Kaplan-Meier survival plots in Hep2G-tumor bearing mice. (PDF)
S3 Table. Volume of HEPG2 tumors in mice treated with $^{225}$Ac-DOTA-TDA emulsion. (PDF)
S4 Table. Volume of HEPG2 tumors in mice treated with ethiodized oil alone. (PDF)
S5 Table. Volume of HEPG2 tumors in mice treated with Saline. (PDF)

Acknowledgments
The Actinium-225 used in this research was supplied by the Isotope Program within the Office of Nuclear Physics in the Department of Energy’s Office of Science. The imaging analysis software, VivoQuant™, is supported through the Hillman Cancer Center In Vivo Imaging Facility, a shared resource at the University of Pittsburgh. We would also acknowledge Kathryn E. Day and Max Rose for their support on the SPECT image analysis.

Author Contributions
Conceptualization: Yong Du, Eleni Liapi, Jessie R. Nedrow.
Data curation: Yong Du, Angel Cortez, Anders Josefsson, Mohammadreza Zarisfi, Jessie R. Nedrow.
Formal analysis: Yong Du, Angel Cortez, Anders Josefsson, Rebecca Krimins, Eleni Liapi, Jessie R. Nedrow.
Funding acquisition: Jessie R. Nedrow.
Investigation: Yong Du, Angel Cortez, Anders Josefsson, Mohammadreza Zarisfi, Rebecca Krimins, Eleni Liapi, Jessie R. Nedrow.
Methodology: Yong Du, Rebecca Krimins, Eleni Liapi, Jessie R. Nedrow.
Project administration: Angel Cortez, Jessie R. Nedrow.
Resources: Rebecca Krimins, Eleni Liapi, Jessie R. Nedrow.

Software: Yong Du.

Supervision: Jessie R. Nedrow.

Validation: Angel Cortez, Eleni Liapi, Jessie R. Nedrow.

Visualization: Yong Du, Angel Cortez, Anders Josefsson, Eleni Liapi, Jessie R. Nedrow.

Writing – original draft: Yong Du, Angel Cortez, Anders Josefsson, Eleni Liapi, Jessie R. Nedrow.

Writing – review & editing: Yong Du, Angel Cortez, Anders Josefsson, Mohammadreza Zar- isfi, Rebecca Krimins, Eleni Liapi, Jessie R. Nedrow.

References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011; 61(2):69–90. https://doi.org/10.3322/caac.20107 PMID: 21296855

2. Center MM, Jemal A. International trends in liver cancer incidence rates. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2011; 20(11):2362–8. https://doi.org/10.1158/1055-9965.EPI-11-0643 PMID: 21921256

3. De P, Dryer D, Otterstatter MC, Semenciw R. Canadian trends in liver cancer: a brief clinical and epidemiologic overview. Curr Oncol. 2013; 20(1):e40–3. https://doi.org/10.3747/co.20.1190 PMID: 23443230

4. Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA: a cancer journal for clinicians. 2012. https://doi.org/10.3322/caac.20141 PMID: 22281605

5. Liapi E, Geschwind JFH. Transcatheter and ablative therapeutic approaches for solid malignancies. J Clin Oncol. 2007; 25(8):978–86. https://doi.org/10.1200/JCO.2006.09.8657 PMID: 17350947

6. Lee KH, Liapi EA, Cornell C, Reb P, Buijs M, Vossen JA, et al. Doxorubicin-loaded QuadraSphere microspheres: plasma pharmacokinetics and intratumoral drug concentration in an animal model of liver cancer. Cardiovasc Intervent Radiol. 2010; 33(3):576–82. https://doi.org/10.1007/s00270-010-9794-1 PMID: 20087738

7. Liapi E, Georgiadis CC, Hong K, Geschwind JF. Transcatheter arterial chemoembolization: current technique and future promise. Tech Vasc Interv Radiol. 2007; 10(1):2–11. https://doi.org/10.1053/j.tvir.2007.08.008 PMID: 17980314

8. Gaba RC, Schwind RM, Ballet S. Mechanism of Action, Pharmacokinetics, Efficacy, and Safety of Transarterial Therapies Using Ethiodized Oil: Preclinical Review in Liver Cancer Models. J Vasc Interv Radiol. 2018; 29(3):413–24. https://doi.org/10.1016/j.jvir.2017.09.025 PMID: 29289495

9. de Baere T, Dufaux J, Roche A, Cournord JL, Berthault MF, Denys A, et al. Circulatory alterations induced by intra-arterial injection of iodized oil and emulsions of iodized oil and doxorubicin: experimental study. Radiology. 1995; 194(1):165–70. https://doi.org/10.1148/radiology.194.1.7997545 PMID: 7997545

10. Lewandowski RJ, Geschwind JF, Liapi E, Salem R. Transcatheter intraarterial therapies: rationale and overview. Radiology. 2011; 259(3):641–57. https://doi.org/10.1148/radiol.11081489 PMID: 21602502

11. Marelli L, Shusang V, Buscombe JR, Cholongitas E, Stigliano R, Davies N, et al. Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer. J Nucl Med. 2009; 50(6):871–7. https://doi.org/10.2967/jnumed.108.060558 PMID: 19443599

12. Bernal P, Raoul JL, Vidmar G, Sereegotov E, Sundram FX, Kumar A, et al. Intra-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma: results of an IAEA-sponsored multinational study. Int J Radiat Oncol Biol Phys. 2007; 69(5):1448–55. https://doi.org/10.1016/j.ijrobp.2007.05.009 PMID: 17692473

13. Zanzonico PB, Divgi C. Patient-specific radiation dosimetry for radionuclide therapy of liver tumors with intrahepatic artery rhenium-188 lipiodol. Semin Nucl Med. 2008; 38(2):S30–9. https://doi.org/10.1053/j.semnuclmed.2007.10.005 PMID: 18243841

14. Bernal P, Raoul JL, Star J, Sereegotov E, Sundram FX, Kumar A, et al. International Atomic Energy Agency-sponsored multinational study of intra-arterial rhenium-188-labeled lipiodol in the treatment of inoperable hepatocellular carcinoma: results with special emphasis on prognostic value of dosimetric...
15. Sofou S. Radionuclide carriers for targeting of cancer. Int J Nanomedicine. 2008; 3(2):181–99. https://doi.org/10.2147/ijn.s2736 PMID: 18686778

16. McDevitt MR, Sgouros G, Sofou S. Targeted and Nontargeted alpha-Particle Therapies. Annu Rev Biomed Eng. 2018; 20:73–93. https://doi.org/10.1146/annurev-bioeng-062117-120931 PMID: 29345977

17. [Cancer of the prostate. Xofigo in the hospitals]. Perspect Infirm. 2015; 12(5):61. PMID: 26730434

18. Radium—223 (Xofigo) for prostate cancer. Med Lett Drugs Ther. 2013; 55(1426):79–80. PMID: 24081388

19. Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Apostolidis C, Weichert W, et al. Targeted alpha-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding. J Nucl Med. 2017; 58(10):1624–31. https://doi.org/10.2967/jnumed.117.191395 PMID: 28408529

20. de Jong HW, Beekman FJ, Viergever MA, van Rijk PP. Simultaneous (99m)Tc/(201)Tl dual-isotope SPET with Monte Carlo-based down-scatter correction. Eur J Nucl Med Mol Imaging. 2002; 29(8):1063–71. https://doi.org/10.1007/s00259-002-0834-1 PMID: 12173021

21. Grogna M, Cloots R, Luxen A, Jérôme C, Desreux J-F, Detrembleur C. Design and synthesis of novel DOTA(Gd3+)–polymer conjugates as potential MRI contrast agents. Journal of Materials Chemistry. 2011; 21(34):12917–26.

22. Josefsson A, Nedrow JR, Park S, Banerjee SR, Rittenbach A, Jammes F, et al. Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer. Cancer Res. 2016; 76(2):472–9. https://doi.org/10.1158/0008-5472.CAN-15-2141 PMID: 26554829

23. Nedrow JR, Josefsson A, Park S, Back T, Hobbs RF, Brayton C, et al. Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model. EJNMMI Res. 2017; 7(1):57. https://doi.org/10.1186/s13550-017-0303-2 PMID: 28721684

24. Lee KH, Liapi E, Buijs M, Vossen J, Hong K, Georgiadis C, et al. Considerations for implantation site of VX2 carcinoma into rabbit liver. J Vasc Interv Radiol. 2009; 20(1):113–7. https://doi.org/10.1016/j.jvir.2008.09.033 PMID: 19028118

25. Vija AH, Hawman EG, Engdahl JC, editors. Analysis of a SPECT OSEM reconstruction method with 3D beam modeling and optional attenuation correction: phantom studies. 2003 IEEE Nuclear Science Symposium Conference Record (IEEE Cat No03CH37515); 2003 19–25 Oct. 2003.

26. Plyku D, Hobbs RF, Huang K, Atkins F, Garcia C, Sgouros G, et al. Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in (124)I PET/CT-Based Dosimetry for (131)I Therapy of Metastatic Differentiated Thyroid Cancer. J Nucl Med. 2017; 58(7):1146–54. https://doi.org/10.2967/jnumed.116.179366 PMID: 28104741

27. Josefsson A, Hobbs RF, Ranka S, Schwarz BC, Plyku D, Willegaignon de Amorim de Carvalho J, et al. Comparative Dosimetry for (68)Ga-DOTATATE: Impact of Using Updated ICRP Phantom, S Values, and Tissue-Weighting Factors. J Nucl Med. 2018; 59(8):1281–8. https://doi.org/10.2967/jnumed.117.203893 PMID: 29439017

28. Martin YC. Exploring QSAR: Hydrophobic, Electronic, and Steric Constants C. Hansch A, Leo, and Hoekman D. American Chemical Society, Washington, DC. 1995. Xix + 348 pp. 22 × 28.5 cm. Exploring QSAR: Fundamentals and Applications in Chemistry and Biology. C. Hansch and A. Leo. American Chemical Society, Washington, DC. 1995. Xvi + 557 pp. 18.5 × 26 cm. ISBN 0-8412-2993-7 (set). $99.95 (set). Journal of Medicinal Chemistry. 1996; 39(5):1189–90.

29. Liapi E, Geschwind JF. Combination of local transcatheter arterial chemoembolization and systemic anti-angiogenic therapy for unresectable hepatocellular carcinoma. Liver Cancer. 2012; 1(3–4):201–15. https://doi.org/10.1159/000335501 PMID: 24159586

PLOS ONE | https://doi.org/10.1371/journal.pone.0261982 January 21, 2022 14 / 16
33. Liapi E, Geschwind JF. Intra-arterial therapies for hepatocellular carcinoma: where do we stand? Ann Surg Oncol. 2010; 17(5):1234–46. https://doi.org/10.1245/s10434-010-0977-4 PMID: 20405328

34. Kim DY, Han KH. Transarterial chemoeMBOLization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality. Hepatol Int. 2016; 10(6):883–92. https://doi.org/10.1007/s12072-016-9722-9 PMID: 27126821

35.Ballangrud AM, Yang WH, Charlton DE, McDevitt MR, Hamacher KA, Panageas KS, et al. Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591). Cancer Res. 2001; 61(5):2008–14. PMID: 11280760

36. Ballangrud AM, Yang WH, Hamacher KA, McDevitt MR, Ma D, Scheinberg DA, et al. Relative efficacy of the alpha-particle emitters Bi-213 and Ac-225 for radioimmunotherapy against micrometastases. Proc AACR. 2000; 41:289.

37. Bloomer WD, McLaughlin WH, Adelstein SJ, Wolf AP. Therapeutic applications of Auger and alpha-emitting radionuclides. Strahlentherapie. 1984; 160(12):755–7. PMID: 6393458

38. Bloomer WD, McLaughlin WH, Neirinckx RD, Adelstein SJ, Gordon PR, Ruth TJ, et al. Astatine-211—tellurium radiocolloid cures experimental malignant ascites. Science. 1981; 212(4492):340–1. https://doi.org/10.1126/science.7209534 PMID: 7209534

39. Humm JL, Chin LM. A model of cell inactivation by alpha-particle internal emitters. Radiat Res. 1993; 134(2):143–50. PMID: 8488249

40. Kassis AI, Harris CR, Adelstein SJ, Ruth TJ, Lambrecht R, McDevitt MR, et al. Radiobiology of Astatine-211 Decay. Radiation Research. 1986; 105(1):27–36. PMID: 3945725

41. Kozak RW, Atcher RW, Gansow OA, Friedman AM, Hines JJ, Waldmann TA. Bismuth-212-Labeled Anti-Tac Monoclonal Antibody—Alpha-Particle Emitting Radionuclides As Modalities for Radioimmunotherapy. Proceedings of the National Academy of Sciences of the United States of America. 1986;83(2):474–8.

42. Kurtzman SH, Russo A, Mitchell JB, DeGraff W, Brechbiel MW, et al. Tumor therapy with targeted atomic nanogenerators. Science. 2001; 294(5546):1537–40. https://doi.org/10.1126/science.1064126 PMID: 11711678

43. Raju YR, Eisen Y, Carpenter S, Inker TC. Radiobiology of alpha-particles. 3. Cell Inactivation by Alpha-Particle Traversals of the Cell-Nucleus. Radiation Research. 1991; 128(2):204–9. PMID: 1947017

44. Ballangrud AM, Yang WH, Palm S, Enom R, Borchardt PE, Pellegrini VA, et al. Alpha-particle Emitting Atomic Generator (Actinium-225)-Labeled Trastuzumab (Herceptin) Targeting of Breast Cancer Spheroids: Efficacy versus HER2/neu Expression. Clin Cancer Res. 2004; 10(13):4489–97. https://doi.org/10.1158/1078-0432.CCR-03-0806 PMID: 15240541

45. Imam SK. Advancements in cancer therapy with alpha-emitters: a review. IntJ RadiatOncol BiolPhys. 2001; 51(1):271–8. https://doi.org/10.1016/s0360-3016(01)01585-1 PMID: 1156878

46. McDevitt MR, Sgouros G, McLaughlin WH, Adelstein SJ, Humm JL, Juric JG, Larson SM, et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med. 1998; 25(9):1341–51. https://doi.org/10.1007/s002590050306 PMID: 9724387

47. Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, Panageas KS, et al. Sequential cytarbaine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res. 2010; 16(21):5303–11. https://doi.org/10.1158/1078-0432.CCR-10-0382 PMID: 20858843

48. Sgouros G. Alpha-particles for targeted therapy. Adv Drug Deliv Rev. 2008; 60(12):1402–6. https://doi.org/10.1016/j.addr.2008.04.007 PMID: 18541332

49. Milevic D, Garusti K, Brady ED, Albert PS, Abdulla A, Flynn J, et al. Potentiation of high-LET radiation by gemcitabine: targeting HER2 with trastuzumab to treat disseminated peritoneal disease. Clin Cancer Res. 2007; 13(6):1926–35. https://doi.org/10.1158/1078-0432.CCR-06-2300 PMID: 17363549

50. Kratochwil C, Giesel FL, Bruchertseifer F, Mier W, Apostolidis C, Boll R, et al. Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging. 2014; 41(11):2106–19. https://doi.org/10.1007/s00259-014-2857-9 PMID: 25070685
53. Park C, Choi SI, Kim H, Yoo HS, Lee YB. Distribution of Lipiodol in hepatocellular carcinoma. Liver. 1990; 10(2):72–8. https://doi.org/10.1111/j.1600-0676.1990.tb00439.x PMID: 2161978

54. Imaeda T, Yamawaki Y, Seki M, Goto H, Inuma G, Kanematsu M, et al. Lipiodol retention and massive necrosis after lipiodol-chemoembolization of hepatocellular carcinoma: correlation between computed tomography and histopathology. Cardiovasc Intervent Radiol. 1993; 16(4):209–13. https://doi.org/10.1007/BF02602962 PMID: 8402781

55. Jeong JM, Kim YJ, Lee YS, Ko JI, Son M, Lee DS, et al. Lipiodol solution of a lipophilic agent, (188)Re-TDD, for the treatment of liver cancer. Nucl Med Biol. 2001; 28(2):197–204. https://doi.org/10.1016/s0969-8051(00)00208-0 PMID: 11295430

56. Ocak M, Toklu T, Demirci E, Selçuk N, Kabasakal L. Post-therapy imaging of 225Ac-DOTATATE treatment in a patient with recurrent neuroendocrine tumor. European Journal of Nuclear Medicine and Molecular Imaging. 2020; 47(11):2711–2. https://doi.org/10.1007/s00259-020-04725-x PMID: 32123970

57. Robertson AKH, Ramogida CF, Rodriguez-Rodriguez C, Blinder S, Kunz P, Sossi V, et al. Multi-isotope SPECT imaging of the (225)Ac decay chain: feasibility studies. Phys Med Biol. 2017; 62(11):4406–20. https://doi.org/10.1088/1361-6560/aa6a99 PMID: 28362640